The effects of the arousal-promoting peptide hypocretin on brain stem G protein activation and ACh release were examined using 16 adult Sprague-Dawley rats. In vitro [
Introduction
The hypothalamic neuropeptides hypocretin (hcrt)-1 and hcrt-2 (de , also named orexin-A and orexin-B (Sakurai et al., 1998) , are thought to participate in the regulation of behavioural arousal . In animals, intracranial administration of hcrt increases wakefulness (Hagan et al., 1999; Bourgin et al., 2000; Piper et al., 2000; Espan Äa et al., 2001; Xi et al., 2001) , and experimentally induced losses of hcrt neurons disrupt wakefulness (Gerashchenko et al., 2001; Hara et al., 2001) . Animal models of the human sleep disorder narcolepsy are characterized by defective hcrt receptors (Lin et al., 1999) or a lack of the peptide (Chemelli et al., 1999) , and human narcoleptic patients show low or undetectable hcrt levels in cerebrospinal¯uid (Nishino et al., , 2001 ) and a loss of hcrt neurons Thannickal et al., 2000) . The clinical phenotype of narcolepsy includes excessive daytime sleepiness, disrupted nighttime sleep and the onset of rapid eye movement (REM) sleep periods or traits directly from wakefulness (Nishino & Mignot, 1997) . Narcolepsy can be viewed as a disorder of the normal boundaries between different arousal states, and it has been suggested that the loss of hypocretin in narcolepsy may facilitate inappropriate transitions between wakefulness and sleep (Scammell, 2003) .
The mechanisms by which hcrt regulates states of arousal are not well understood. Hcrt-synthesizing neurons project to arousal-promoting brain stem nuclei including the dorsal raphe nucleus (DR), locus coeruleus (LC) and pontine reticular nucleus, oral part (PnO) and caudal part (PnC) . Hcrt excites noradrenergic LC (Hagan et al., 1999; Horvath et al., 1999) and serotonergic DR (Brown et al., 2001) neurons, and may promote wakefulness by elevating monoaminergic tone . Hcrt-1 microinjection into cat pontine reticular formation triggers REM sleep (Xi et al., 2002) , suggesting that hcrt-1 may also promote brain activation by enhancing pontine cholinergic neurotransmission .
Hcrt binds two guanine nucleotide binding protein (G protein)-coupled receptors, hcrt-r1 and hcrt-r2 (Sakurai et al., 1998) . Hcrt-r1 shows a higher af®nity for hcrt-1 than for hcrt-2, whereas hcrt-r2 shows equally high af®nity for both peptides (Sakurai et al., 1998) . In vitro 
Materials and methods

Chemicals and animals
Hcrt-1 was purchased from California Peptide Research (Napa, CA, USA). SB-334867 was provided by GlaxoSmithKline (Essex, UK). Re¯ection autoradiography ®lm (Kodak X-OMAT Blue XB-1) and [
35 S]GTPgS were obtained from PerkinElmer Life Science Products (Boston, MA, USA). Carbachol, guanosine 5 H -diphosphate (GDP), guanosine 5
H -O-(g-thio)triphosphate (GTPgS), and chemicals used for buffers, Ringer's solution, standard curves and mobile phase were purchased from Sigma-Aldrich (St Louis, MO, USA). Adult male Sprague-Dawley rats (250±350 g) were purchased from Charles River Laboratories (Wilmington, MA, USA) and housed in a 12-h light±dark cycle for at least 1 week prior to use. All experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Academy Press, Washington, DC, 1996) and with approval by the University of Michigan Committee on Use and Care of Animals.
Preparing tissue sections and performing in vitro [ 35 
S]GTPgS autoradiography
Rats were always decapitated at the same time of day (4±5 h after light onset). Brains were removed and immediately frozen in a bilayer composed of 2-methylbutane and 1-bromobutane at À30 8C. Coronal brain stem sections (20 mm thick) were cut serially using Hacker Bright (Fair®eld, NJ, USA) or Leica CM3050 S (Leica Microsystems, Nussloch, Germany) cryostats. Adjacent pairs of sections from approximately bregma À10.30 to À7.04 mm (Paxinos & Watson, 1998) were thaw-mounted onto gelatin-coated glass slides, dried in a vacuum desiccator (4 8C) and stored at À70 8C before being used in an assay.
[ 35 S]GTPgS binding assays were performed as previously described (Sim et al., 1995; Capece et al., 1998; Bernard et al., 2002a) . Assay buffer contained 50 mM Tris-HCl, 3 mM MgCl, 0.2 mM EGTA and 100 mM NaCl (pH 7.4). Slide-mounted tissue sections were brought to room temperature and incubated for 2 h in 0.04 nM [
35 S]GTPgS and 2 mM GDP. Different drug treatments during the 2-h incubation were applied for the concentration±response assays and for the antagonist blocking assays, as described below. For all assays, the incubation period was terminated by rinsing tissue sections in ice-cold 50 mM Tris-HCl buffer (pH 7.0) followed by ice-cold deionized water.
For the concentration±response assays, tissue sections were assigned serially to one of seven assay conditions. The ®rst assay condition determined basal [
35 S]GTPgS binding in the absence of an exogenous agonist. Conditions two to ®ve contained hcrt-1 (2, 20, 200 or 2000 nM, respectively) to test the hypothesis that hcrt-1-stimulated G protein activation is concentration-dependent. Condition six used the cholinergic agonist carbachol (1 mM) as a positive assay control (Capece et al., 1998) . Assay condition seven determined nonspeci®c binding using excess unlabelled GTPgS (10 mM).
For the study designed to test the hypothesis that hcrt-1-stimulated G protein activation can be blocked by the speci®c hcrt receptor antagonist SB-334867, tissue sections were assigned serially to one of ®ve assay conditions: basal, nonspeci®c binding, hcrt-1 (200 nM), SB-334867 (2 mM), and hcrt-1 (200 nM) SB-334867 (2 mM). SB-334867 is poorly soluble in water, requiring the use of dimethyl sulfoxide (DMSO) (Duxon et al., 2001) . To control for nonspeci®c effects of DMSO on [
35 S]GTPgS binding, the buffer used for all ®ve assay conditions contained 0.02% DMSO.
Post-assay processing of the tissue sections included drying, exposing to autoradiography ®lm, and staining. Tissue sections were initially dried in a room-temperature stream of air. The drying process was completed by keeping the sections in a vacuum desiccator overnight. Measuring the effects of hcrt-1 on pontine ACh release Every microdialysis experiment was performed according to the following series of procedures. After quantifying the percentage of ACh recovered in vitro by a dialysis probe, a rat was anaesthetized and the probe was aimed stereotaxically for either the left or right PnO; details are given below. In vivo dialysis samples were collected and immediately analysed for ACh content. The dialysis probe was removed from the brain and probe recovery of ACh again was determined in vitro. Each rat was used for only one experiment. Placement of the dialysis probe in the PnO was con®rmed histologically. These steps are described in detail below.
Using in vivo microdialysis to deliver hcrt-1 to the pons and collect ACh from the pons CMA/11 microdialysis probes (1 mm length, 0.24 mm membrane diameter, 6 kDa cut-off; CMA Microdialysis, North Chelmsford, MA, USA) were connected to a CMA/100 pump which provided a constant 2.0 mL/min¯ow rate. Probes were perfused continuously with either Ringer's solution (147 mM NaCl, 4.0 mM KCl, 2.4 mM CaCl 2 , 10 mM neostigmine bromide, pH 5.8±6.2) or with hcrt-1 (100 mM) dissolved in Ringer's solution and adjusted to pH 5.8±6.2 with NaOH. Dialysis samples (30 mL) were collected every 15 min. Before positioning the dialysis probe in the brain, the probe was placed in a solution of known ACh concentration and ®ve 30-mL samples were collected and analysed for ACh. These data were used to calculate percentage of ACh recovered by the probe. Rats were deeply anaesthetized with 3±4% iso¯urane (Abbott Laboratories, North Chicago, IL, USA) in 100% O 2 and placed in a Model 962 ultra-precise small-animal stereotaxic instrument (David Kopf Instruments, Tujunga, CA, USA) equipped with a Model 920 rat adaptor, anaesthesia mask and ear bars. A warm water blanket (37 8C) connected to a re-circulating heat pump system (Gaymar Industries, Orchard Park, NY, USA) was used to maintain body temperature during anaesthesia. Delivered iso¯urane concentration and core body temperature were measured using a Cardiocap TM /5 monitor (DatexOhmeda, Madison, WI, USA). Respiratory rate (breaths/min) was counted manually every 15 min. The scalp was opened and an access hole for the dialysis probe was made through the skull using a Dremel (Racine, WI, USA). A dialysis probe was aimed for the PnO according to the following stereotaxic coordinates: 8.6 mm posterior to bregma, 1.2 mm lateral from the midline and 9.2 mm ventral to bregma (Paxinos & Watson, 1998) .
After the dialysis probe was in the brain, delivered iso¯urane concentration was set at 1.5% and held constant during sample collection. Dialysis samples were collected for at least 45 min to ensure stable ACh levels. Five control samples (75 min) then were collected during dialysis with Ringer's solution before hcrt-1 delivery was initiated by turning a CMA/110 liquid switch. Five dialysis samples (75 min) were collected during hcrt-1 delivery. When the dialysis probe was removed from the brain, the scalp wound was closed using sutures. Animals were allowed to recover from anaesthesia and survive 3±4 days to permit formation of a glial scar at the site where the dialysis probe had been placed.
Immediately following removal of the dialysis probe from the brain, the probe was placed in a solution of known ACh concentration and ®ve dialysis samples were collected and analysed for ACh. Comparison between pre-and postexperimental probe recoveries by twosample Student's t-test (P < 0.05) ensured that changes in ACh release measured during each experiment resulted from drug administration and not from intraexperimental changes in the dialysis membrane (Vazquez & Baghdoyan, 2003) . The present study includes only experiments where pre-and postexperimental probe recoveries did not change signi®cantly in the hypothesized direction of the drug effect.
Quantifying ACh
Dialysis samples were analysed by high performance liquid chromatography with electrochemical detection (Bioanalytical Systems (BAS), West Lafayette, IN, USA, as previously described Vazquez & Baghdoyan, 2003) . ACh was converted proportionally into H 2 O 2 by an immobilized enzyme reactor column and H 2 O 2 was detected amperometrically by a platinum electrode (0.5 V) in reference to a Ag /AgCl electrode. The subsequent chromatographic signal was digitized and quanti®ed using ChromGraph 1 software (BAS) and a ®ve-point standard curve (0.1±1.0 pmol ACh) created before each experiment. Differences in ACh before and during hcrt-1 administration were evaluated using paired t-test. The alpha level for statistical signi®cance was P < 0.05.
Histologically identifying dialysis probe sites
Rats were killed with an overdose of anaesthetic, and brains were removed for veri®cation of probe placement. Brains were frozen immediately after removal and cut serially as 40-mm coronal sections using a Leica cryostat. Sections then were ®xed using paraformaldehyde vapors (80 8C), stained with Cresyl Violet, and visually inspected for evidence of a dialysis probe-induced lesion. Every section containing a lesion was digitized using a Cohu CCD camera with a Micro Nikon 60-mm objective. Digitized sections were compared with coronal plates from a rat brain atlas (Paxinos & Watson, 1998) to determine the stereotaxic coordinates for each dialysis site.
Results
Hcrt-1-induced G protein activation was concentrationdependent and blocked by the hcrt receptor antagonist SB-334867 Fig. 2A) , 58% in LC (Fig. 2B ), 44% in PnC (Fig. 2C ) and 52% in PnO (Fig. 2D) . Fig. 3A; F 3,23 20.0, P < 0.0001), LC ( Fig. 3B ; F 3,19 8.9, P 0.002), PnC ( Fig. 3C ; F 3,23 22.6, P < 0.0001) and PnO ( Fig. 3D ; F 3,23 24.7, P < 0.0001). SB-334867 did not alter [
35 S]GTPgS binding in any nucleus studied.
Microdialysis delivery of hcrt-1 increased ACh release in the pontine reticular formation
The demonstration that in vitro treatment with hcrt-1 caused a concentration-dependent activation of G proteins in arousal-related nuclei encourages investigations into the functional consequences of in vivo hcrt-1 administration. Therefore, this study used dialysis to deliver hcrt-1 to the PnO while measuring ACh release in the PnO. Figure 4 summarizes histological data con®rming that all dialysis sites were restricted to the PnO. The effect of hcrt-1 (100 mM) on ACh release is shown in Fig. 5 . Chromatographic peaks representing ACh in one sample obtained during dialysis with Ringer's (control) and one sample collected during dialysis delivery of hcrt-1 are presented in Fig. 5A . Figure 5B illustrates the time course of ACh release during one typical experiment. Each bar represents sequential ACh samples collected for 15 min. By the second sampling interval during dialysis delivery of hcrt-1, ACh release was clearly increased over control levels. Figure 5C summarizes data from six microdialysis experiments. Hcrt-1 signi®cantly increased ACh release by an average of 87% (t 5 5.6, P < 0.002). Hcrt-1 had no signi®cant effect on respiratory rate or core body temperature.
Discussion
The data reported here show that hcrt-1-induced [ 35 S]GTPgS binding in DR, LC and pontine reticular formation is concentration-dependent and blocked by a selective hcrt receptor antagonist. This is the ®rst demonstration that, in brain stem nuclei known to regulate states of arousal, hcrt-1 activates G proteins as a consequence of speci®c receptor interactions. These results indicate that some hcrt receptors in the brain stem may couple to inhibitory (Gi-like) G proteins. This study also showed that in vivo administration of hcrt-1 to the pontine reticular formation increased ACh release in the pontine reticular formation. This ®nding suggests that hcrt may promote arousal by, in part, enhancing pontine cholinergic neurotransmission. The following discussion considers some of the strengths and limitations of the data, implications of the ®ndings for G protein coupling of hcrt receptors, and inferences for arousal state control.
Hcrt-1-stimulated G protein activation is receptor-mediated
One advantage of in vitro [
35 S]GTPgS autoradiography is that brain anatomy is preserved. Consequently, agonist-stimulated G protein activation can be quanti®ed in speci®c histologically de®ned brain regions (Fig. 1) . The present data show that for DR, LC, PnO and PnC, hcrt-1 caused a signi®cant increase in [ 35 S]GTPgS binding which was concentration-dependent, reached saturation, and was ®tted by a sigmoid curve (Fig. 2) . Any biological process downstream from receptor binding which follows the law of mass action will exhibit a sigmoid shape when plotted as a semilogarithmic concentration± response curve (Taylor & Insel, 1990 ). This study therefore provides the ®rst direct evidence that hcrt-1-stimulated [ 35 
S]GTPgS binding in DR, LC, PnO and PnC is receptor-mediated.
Con®rmation of a receptor-mediated response also is obtained by demonstrating pharmacological antagonism of the response (Limbird, 1996) . This study used the competitive antagonist SB-334867 to demonstrate that hcrt-1-induced G protein activation is receptor-mediated. SB-334867 has been shown to block electrophysiological (Sof®n et al., 2002) and behavioural (Rodgers et al., 2001) responses to hcrt. Treatment of tissue sections with hcrt-1 plus SB-334867 reduced [ 35 S]GTPgS binding to basal levels in all four brain stem nuclei (Fig. 3) , providing the ®rst autoradiographic demonstration that hcrt-1-stimulated G protein activation can be pharmacologically antagonized. The present ®nding of antagonist blocking agrees with data showing that another hcrt receptor antagonist, NBI 36487, blocked hcrt-stimulated [
35 S]GTPgS binding in homogenates of rat pons (Shiba et al., 2002) . SB-334867 alone had no effect on (Fig. 3) , consistent with reports that SB-334867 has no agonist activity .
Hcrt-1 activated G proteins in additional brain stem nuclei G proteins were activated by hcrt-1 in regions medial to the LC, including the PDTg (Fig. 1) . Some authors consider the PDTg of rat to be a homologue of the human dorsal tegmental nucleus, which relays autonomic impulses from the hypothalamus to the reticular formation (Huang et al., 1992) . Hcrt-positive ®bres have been reported in the intermediolateral cell column of the spinal cord in association with preganglionic sympathetic ®bres (Date et al., 2000) . Activation of PDTg also is consistent with functional studies indicating that hcrt excites sympathetic neurons (Antunes et al., 2001) .
More rostrally in the brain stem, hcrt-1 activated regions near but outside the boundaries of the DR, including the VLPAG (Fig. 1) . VLPAG plays a key role in nociceptive processing (Klamt & Prado, 1990) . G proteins in VLPAG of mouse and rat are activated by the cholinergic agonist carbachol (DeMarco et al., 2003) , and cholinergic antinociception has been demonstrated in rat (Ishizawa et al., 2000) . The present observation that hcrt-1 activated G proteins in VLPAG of Hcrt-1 modulates pontine G proteins and ACh release 1779 rat is consistent with recent evidence that hcrt-1 can have antinociceptive effects (Yamamoto et al., 2002) .
Finally, Fig. 1 shows that hcrt-1 activated G proteins in the MnR. Hcrt is a hypothalamic neuropeptide and hcrt-1 activation of G proteins in MnR is consistent with neuroanatomical data showing that MnR is the primary target of lateral hypothalamic ®bres projecting to the brain stem (Vertes et al., 1999) . Functional studies indicate that MnR activates hippocampus by mechanisms which include GABA A - (Kinney et al., 1995) and GABA B (Varga et al., 2002) -mediated inhibition of serotonin-containing neurons.
It has been postulated that hcrt contributes to the regulation of arousal states, feeding and sensory±motor processing (Sakurai et al., 1998; Hagan et al., 1999; Yamamoto et al., 2002) . Because these diverse functions involve regulation by a plethora of brain stem nuclei, it was anticipated that hcrt-1 would cause widespread activation of G proteins. The presently reported hcrt-stimulated G protein activation in multiple brain stem nuclei is consistent with the extensive regional distribution pattern of hcrt terminals , receptor mRNA (Trivedi et al., 1998; Marcus et al., 2001) and receptor protein .
Two controls facilitate functional interpretation of the [ 35 S]GTPgS data. First, the cholinergic agonist carbachol was used as a positive control to con®rm assay conditions, because carbachol has previously been shown to activate G proteins in pontine brain stem of rat (Capece et al., 1998) and mouse (DeMarco et al., 2003) . In the present study, carbachol increased [
35 S]GTPgS binding over basal levels in DR, LC, PnC and PnO by 77, 72, 94 and 74%, respectively, indicating that the assay was successful. Second, the in vitro autoradiography experiments included a brain region control. Figure 1 clearly shows lack of activation in the ®bre pathway comprised of the facial nerve (7n).
Hcrt receptors and G protein subtypes
Hcrt-r1 and hcrt-r2 both signal through heterotrimeric G proteins (Sakurai et al., 1998) . G proteins are classi®ed into subtypes based on the selective interaction of the alpha subunit with a downstream signalling effector molecule (Farfel et al., 1999) . The G protein subtypes coupled to hcrt receptors are still under investigation (reviewed in Kukkonen et al., 2002) . Studies using hypothalamic neuronal cell cultures provided evidence that hcrt receptors increase intracellular calcium by coupling to Gq-like G proteins . Hcrt receptors have also been shown to cause direct activation of a calcium in¯ux pathway (Lund et al., 2000) . Recent in vitro work using rat (Nanmoku et al., 2000) or human Mazzocchi et al., 2001; Randeva et al., 2001 ) peripheral tissue suggests that hcrt receptors interact with Gi-like G proteins.
Agonist-activated [ 35 S]GTPgS binding is thought to preferentially label inhibitory G proteins (Kurkinen et al., 1997; Waeber & Moskowitz, 1997; Laitinen et al., 2001) . Accordingly, the present ®nding that hcrt-1 causes a concentration-dependent antagonist-sensitive increase in [
35 S]GTPgS binding may indicate that some hcrt receptors in rat brain stem couple to Gi-like G proteins. Several lines of evidence support this possibility. First, hcrt-induced stimulation of [ 35 S]GTPgS binding has also been demonstrated using Chinese hamster ovary cells expressing human hcrt-r2 and using homogenates of rat pons and midbrain (Shiba et al., 2002) . Second, recent electrophysiological studies in human embryonic kidney (HEK) cell lines transfected with hcrt-r1 and hcrt-r2 revealed that pertussis toxin (PTX) blocked the hcrt-1-induced conductance increase (Hoang et al., 2003) . Because PTX blocks inhibitory G proteins, this ®nding suggests that hcrt-r1 and hcrt-r2 can couple to multiple G protein subtypes, including Gi-like G proteins (Hoang et al., 2003) . Third, in vitro studies in rat sympathetic preganglionic neurons showed that PTX pretreatment abolished hcrt-1-induced depolarization (van den Top et al., 2003) . Fourth, preliminary autoradiographic data indicate that hcrt-1-stimulated [ 35 S]GTPgS binding in rat PnO is blocked by PTX (Bernard et al., 2003b) . Fifth, in addition to its excitatory properties, hcrt-1 has been shown to simultaneously produce synaptic excitation and inhibition in the same set of neurons (Davis et al., 2003) . These complexities illustrate that signalling pathways activated by hcrt-1 may differ in LC, DR and pontine reticular formation, despite involvement of the same G protein subtype. An alternate hypothesis is that hcrt-induced increases in [ of Gi-like G proteins. Indirect activation could result from heterodimerization of hcrt receptors with other G protein-coupled receptors known to activate inhibitory G proteins (Devi, 2001; Angers et al., 2002; Brady & Limbird, 2002) .
ACh release in PnO was modulated by hcrt-1
Having demonstrated that activation of hcrt receptors stimulates G proteins in arousal-related brain stem nuclei, this study next investigated the effect of hcrt-1 on ACh release. Direct administration of hcrt into the pontine brain stem increases either wakefulness or REM sleep, depending upon the nucleus injected. Microinjection of hcrt-1 into rat LC (Bourgin et al., 2000) or cat laterodorsal tegmental nucleus (LDT) (Xi et al., 2001 ) increases wakefulness and suppresses REM sleep. Microinjection of hcrt-1 into a terminal ®eld of cholinergic LDT neurons, the pontine reticular formation, enhances REM sleep in cat (Xi et al., 2002) . Hcrt neurons project to LDT Chemelli et al., 1999) , and hcrt excites cholinergic LDT neurons (Burlet et al., 2002) . Stimulating LDT and pedunculopontine tegmental nucleus (PPT) neurons causes cortical activation (Steriade, 1993) and increases ACh release in the pontine reticular formation (Lydic & Baghdoyan, 1993) . The cortical activation of wakefulness and REM sleep (Moruzzi, 1972; Steriade, 1993) may be facilitated by excitatory hcrt input to these cholinergic brain stem neurons . Cortical ACh release reaches its greatest levels during wakefulness and REM sleep (Jasper & Tessier, 1971; Marrosu et al., 1995) . In the dorsal tegmental ®eld rostral to LC (Kodama et al., 1990) and in the medial pontine reticular formation (Leonard & Lydic, 1997) , ACh release is signi®cantly greater during REM sleep than during wakefulness. ACh release in the medial pontine reticular formation also changes during the transition from halothane anaesthesia to postanaesthesia wakefulness (Keifer et al., 1996) . ACh levels are low during anaesthesia and increase signi®cantly during postanaesthesia wakefulness (Keifer et al., 1996) . Taken together, the ®ndings that (i) pontine reticular formation ACh release is increased during states characterized by cortical arousal (Keifer et al., 1996; Leonard & Lydic, 1997) , (ii) hcrt promotes arousal and (iii) hcrt activates G proteins in the pontine reticular formation (present data) suggested the present hypothesis that hcrt-1 increases ACh release in the pontine reticular formation.
Dialysis administration of hcrt-1 to the PnO caused a signi®cant increase in ACh release within the PnO (Figs 4 and 5) . This is the ®rst demonstration that hcrt-1 modulates the release of endogenous ACh in vivo. The results are compatible with the interpretation that one mechanism by which hcrt promotes arousal is by enhancing cholinergic transmission . The present study did not include any dependent measures of arousal. Future experiments are needed to determine whether hcrt-induced ACh release in the pontine reticular formation is accompanied by cortical and/or behavioural activation. The present ®nding of increased ACh release caused by hcrt-1 is consistent with in vitro data showing that hcrt-1 increased [ 3 H]ACh out¯ow from enteric cholinergic nerve terminals in ileal strips (Matsuo et al., 2002) .
Limitations, methodological considerations and conclusions
The effects of hcrt-1 on ACh release in PnC were not examined in the present study. PnC and PnO comprise the rat pontine reticular formation. The PnO was selected for dialysis because functional mapping studies of rat PnO and PnC have shown that the cholinergically evoked REM sleep-like state can be triggered with the shortest latency and greatest duration only from the caudal part of the PnO (Bourgin et al., 1995) . This functional site-speci®city stands in contrast to the ®nding that M2 muscarinic receptors are expressed throughout the pontine reticular formation with no difference in M2 receptor density between PnO and PnC (Baghdoyan, 1997) . Previous [
35 S]GTPgS studies also showed no difference in the magnitude of carbachol-stimulated G protein activation between PnO and PnC (Capece et al., 1998) .
The present ACh release data were obtained using iso¯urane-anaesthetized rat. Because ACh release in the medial (Leonard & Lydic, 1997) and dorsal tegmental (Kodama et al., 1990) portions of the pontine reticular formation changes signi®cantly across the sleepwake cycle, it was necessary to hold arousal state constant with general anaesthesia in order to distinguish between the effects of hcrt-1 and the effects of arousal state on ACh release. This approach has been used successfully to distinguish between drug-and state-induced changes in ACh release in cat pontine reticular formation and basal forebrain (Vazquez & Baghdoyan, 2003) , rat cortex (Materi et al., 2000) and mouse cortex (Douglas et al., 2001) .
The relatively high concentration of hcrt-1 used for the present microdialysis experiments (100 mM) was selected based on in vitro data demonstrating that <0.1% of a peptide similar in molecular weight to hcrt is delivered through dialysis membranes (Kendrick, 1991) . Thus, the estimated concentration of hcrt-1 delivered to the PnO was %100 nM. Hcrt-1-induced G protein activation in PnO occurred at concentrations ranging from 20 to 2000 nM (Fig. 2D) . Future studies can determine whether the hcrt-1-induced increase in ACh release is concentration-dependent.
Limitations of the microdialysis technique preclude the ability to specify the mechanisms by which hcrt-1 signi®cantly increased ACh release in PnO. Existing data regarding synaptic relationships and neurochemical identity of cells in the dorsolateral pons do, however, permit mechanistic speculation. Hcrt neurons are known to project to the pontine reticular formation Chemelli et al., 1999) , and the pontine reticular formation has been shown to contain hcrt receptors Hervieu et al., 2001) . It is also known that rat PnO contains muscarinic cholinergic receptors samples and for hcrt-1 samples for each experiment, and then across experiments (n 6) to show that hcrt-1 caused a signi®cant ( (Baghdoyan, 1997) and that PnO neurons are not cholinergic (Jones, 1990) . The pontine reticular formation receives cholinergic input from the LDT/PPT (Mitani et al., 1988; Shiromani et al., 1988; Woolf & Butcher, 1989; Jones, 1990; Semba, 1993) , and LDT/PPT neurons release ACh in the pontine reticular formation (Lydic & Baghdoyan, 1993) . Thus, although the synaptic details remain unknown, it is clear that the hcrt-1-stimulated increase in ACh release must involve an effect on LDT/PPT cell bodies, LDT/PPT terminals in the PnO, or both. How might hcrt-1 delivered to the PnO alter LDT/PPT terminals and/or cell bodies? Two possible mechanisms are considered here. First, hcrt-1 may facilitate ACh release by acting directly at hcrt receptors located presynaptically on cholinergic LDT/PPT terminals within PnO. Second, hcrt-1 depolarizes and increases the discharge rate of pontine reticular formation neurons in vivo (Xi et al., 2002) . Pontine reticular formation neurons project to the LDT/PPT nuclei (Semba & Fibiger, 1992) and are thought to be glutamatergic (Kaneko et al., 1989; Stevens et al., 1992) . Glutamate has been shown to excite cholinergic LDT/PPT neurons (Sanchez & Leonard, 1994) . Thus, hcrt delivered by dialysis to the PnO may depolarize PnO neurons which in turn would depolarize LDT/PPT neurons, causing an increase in ACh release from LDT/PPT terminals in the PnO. The ability of PnO to alter LDT/PPT is supported by the ®nding that unilateral microinjection of carbachol into the pontine reticular formation causes increased ACh release in the contralateral pontine reticular formation (Lydic et al., 1991) . The foregoing possible mechanisms are not mutually exclusive and hcrt-1 may modulate ACh release in PnO by a combination of these synaptic relationships. Although speculative, these possibilities are based on existing data and point the way for future experiments aiming to specify synaptic mechanisms by which hcrt-1 modulates ACh release.
The present ®nding that hcrt-1 increases ACh release in the PnO is novel and directly relevant to functional studies showing that hcrt-1 administration to PnO triggers a REM-sleep-like state (Xi et al., 2002) . Whether hcrt-1 increases ACh release by activating an inhibitory G protein-coupled signal transduction pathway remains to be identi®ed. The present results encourage future studies aiming to determine the synaptic location of hcrt receptors within the PnO.
